Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29164178 | 0.92 | ADORA1 (0.49) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL2673712 | 0.87 | ADORA1 (0.46) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL29117283 | 0.85 | ADORA1 (0.42) | ADORA1USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL17729165 | 0.84 | ADORA1 (0.45) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL13315645 | 0.84 | ADORA1 (0.45) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL4509441 | 0.84 | ADORA1 (0.42) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL29924624 | 0.84 | ADORA1 (0.42) | ADORA1USP2SMN1; SMN2GRM5ESR2 | |
| SCHEMBL13315630 | 0.84 | ADORA1 (0.45) | ADORA1USP2SMN1; SMN2ESR2NR1H2 | |
| SCHEMBL13355588 | 0.84 | ADORA1 (0.45) | ADORA1USP2SMN1; SMN2ESR2NR1H2 | |
| SCHEMBL3564075 | 0.82 | ADORA1 (0.41) | ADORA1USP2SMN1; SMN2GRM5ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084146-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-08-21 | — | — | EP | claimed |
| US-8354432-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | claimed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2084146-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8354432-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-20100063067-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| EP-2084146-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2008042925-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | ADORA1 875/4885USP2 4608/4885SMN1; SMN2 4452/4885 |
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | ADORA1 303/4885USP2 3798/4885SMN1; SMN2 1070/4885 |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | ADORA1 67/4885USP2 2898/4885SMN1; SMN2 2854/4885 |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | ADORA1 174/4885USP2 3201/4885SMN1; SMN2 3985/4885 |
| US-20100063067-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CCR1, ACKR3 | ADORA1 63/4885USP2 3644/4885SMN1; SMN2 4432/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | ADORA1 799/4885USP2 4516/4885SMN1; SMN2 4458/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | ADORA1 174/4885USP2 3201/4885SMN1; SMN2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.